# 1. Financial Performance ## A. Key Figures * Consolidated Revenue: ₹14,869 Mn Q2 (+6%) · ₹29,925 Mn H1 (+7%) * Consolidated EBITDA: ₹3,139 Mn Q2 (+6%, 21% margin) · ₹6,817 Mn H1 (23% margin, +300 bps YoY) * Net Profit: ₹1,837 Mn Q2 (12% margin) · ₹3,992 Mn H1 (13% margin, +200 bps YoY) * **Gross Margin:** 63% Q2 (+400 bps) · 64% H1 (+500 bps) * Cash & Equivalents: ₹30,999 Mn (incl. ₹3,960 Mn non-callable) as of Sep-25 * **Cenexi Revenue:** €88 Mn H1 (+10% in EUR) · €40 Mn Q2 (+8% in EUR) * **Cenexi EBITDA Loss:** €5 Mn H1 (vs. €11 Mn prior year) ## B. Revenue Growth * **Broad-Based Momentum:** Consolidated revenue growth driven by resilient U.S. demand and **Cenexi’s double-digit euro-denominated growth**, despite planned site shutdowns. * **Base Business Strength:** Core pharma sales expanded on favorable mix and new high-margin product launches, partially offset by softness in regulated markets. * **New Revenue Inflection:** **Dalbavancin** set to contribute meaningfully in coming quarters, with margins expected to stabilize post ramp-up. ## C. Profit Margins * **Sustained Margin Expansion:** Gross and EBITDA margins improved YoY and sequentially, driven by **favorable product mix**, **automation**, and **operational efficiencies** across manufacturing. * **Base Business Outperformance:** Adjusted EBITDA margin at **~37%**, above 35% target, reflecting portfolio rationalization and strong ROCE discipline. * **Cenexi Turnaround Progress:** EBITDA losses halved YoY, with improvement expected from Q3 as production normalizes and sales scale. * **Cost Pressures Managed:** Employee costs rose 12% YoY but were offset by yield improvements and overhead optimization, particularly at Cenexi. ## D. Cash Flow * **Operational Cash Flow Modest:** Cash from operations was **₹20 Cr in Q2** and **₹30 Cr in H1**, constrained by working capital, though **cash conversion cycle improved to 163 days**. * **Other Income Boost:** **₹2 Cr in Q2** and **₹7 Cr in H1** from forex gains and interest income supported net results. ## E. Balance Sheet * **Strong Liquidity Position:** Robust cash balance of **₹3,900 Cr** provides flexibility for high-ROCE capex in CDMO, GLP-1, and complex injectables. * **Disciplined Capital Structure:** Cenexi carries minimal external debt of **₹40 Cr**, with group capex focused on internal cash generation and value-accretive projects. --- # 2. Product & Launch Performance ## A. Key Figures * **B. S. RTU Filings:** **20** filed (**14** approved, **10** in development) [$659M opportunity] * **Active Product Pipeline:** **15** under development (**7** 505(b)(2), **8** ANDAs) * **Q2 FY'26 Launches:** **7** new molecules launched in U.S. * **GLP-1 Cartridge Capacity:** **4 crore** units operational · **10 crore** under construction (target: **14 crore** by mid-next year) * **GLP-1 Contracts:** **1 signed**, **2 in finalization**, **3 total active** with more in discussion ## B. New Product Launches * **Robust U.S. Momentum:** Strong double-digit product filings and approvals in RTU segment, with recent launch activity reinforcing commercial execution. * **Pipeline Depth:** Active development across **505(b)(2)** and **ANDA** pathways highlights strategic focus on complex generics with high entry barriers. ## C. High-Margin Products * **Value-Led Transition:** Strategic shift toward complex injectables—**RTU, peptides, hormones, ophthalmics**—driving differentiation and pricing power. * **Near-Term Growth Levers:** **Enoxa supply to Civica** and upcoming **Colistimethate** launch with dedicated line signal scalable, high-margin contributions. * **Market Share Trajectory:** RTU products expected to capture **15–20%** initial share, with upside from **GPO contract openings**. ## D. GLP-1 Portfolio Progress * **Top-Tier GLP-1 Positioning:** Commercialized **liraglutide** and advancing **semaglutide** launches in EM/ROW, supported by scalable infrastructure and regulatory strength. * **Capacity Expansion:** Rapid scaling of cartridge capacity to **14 crore units** underscores confidence in long-term demand and partnership pipeline. * **Strong Partner Demand:** Multiple **RFPs and negotiations** with global and Indian firms validate position as preferred GLP-1 CDMO. ## E. Biologics & CDMO Revenue * **CDMO Leadership Push:** Building end-to-end sterile CDMO capabilities, including **auto-injectors** and **pen devices**, to capture high-value outsourcing demand. * **Biologics Revenue Live:** First revenue recognized from **Dr. Reddy’s biologics collaboration** this quarter; partnership progressing well. * **Integrated Reporting:** Biologics revenue embedded in consolidated stream—no separate segment disclosure. --- # 3. Segment & Geography Mix ## A. Key Figures * U.S. Revenue: ₹8,005M Q2 (+8%) · ₹15,176M H1 (+8%) **B. S. Revenue:** ₹5 Cr Q2 (+8%) · ₹16 Cr H1 (+8%) * **Other Regulated Markets Revenue:** ₹2 Cr Q2 (+18%) · ₹4 Cr H1 (+18%) * **Cenexi Revenue:** ₹2 Cr Q2 (+21%) * **ROW Revenue:** ₹5 Cr Q2 (flat) · ₹8 Cr H1 (flat) * **India Revenue:** ₹5 Cr Q2 · ₹8 Cr H1 (6% of base business) ## B. U.S. Market Growth * **Resilient Base Business Growth:** U.S. revenue posted strong momentum, driven by volume expansion and new product launches, with top 10 customers growing at a **19%** pace. * **CDMO Segment Accelerating:** CDMO contributed meaningfully to U.S. growth, with **7%** of last quarter’s 17% increase attributed to tech transfers from established players. * **Growth Moderation in USD Terms:** Reported U.S. growth includes a boost from rupee depreciation; underlying growth in dollar terms is more moderate. * **Strategic Expansion Focus:** Management is actively pursuing inorganic opportunities and GPO partnerships to deepen U.S. market penetration. ## C. Regulated Markets * **Broad-Based Strength in Regulated Regions:** Solid double-digit growth across Europe and the U.S. fueled performance, with Cenexi delivering **21%** revenue growth in rupee terms. * **Temporary Timing Impact:** A shift in Daptomycin shipment timing inflated European growth temporarily; normalization expected in coming quarters. * **Structural Growth Outlook:** Despite recent flatness at **$95 million run rate**, regulated markets are poised for sustained double-digit growth, backed by new CDMO wins in Europe. * **CDMO as Key Growth Engine:** CDMO segment is the primary driver of expansion across combined U.S. and European regulated markets. ## D. Rest of World * **Diverging Revenue Streams:** ROW performance is mixed—**own product sales surged 19%**, but CMO and tech transfer revenue collapsed **53%**, resulting in flat overall growth. * **Strategic Reorientation Underway:** Company is prioritizing high-value product launches and geographic expansion in high-potential regions like Latin America, Southeast Asia, and Africa. * **Long-Term Growth Potential:** Despite near-term headwinds, ROW remains a strategic growth vector with improving trends across emerging markets. ## E. India Business * **Integration and Mix Optimization:** Cenexi is shifting toward higher-margin products and aligning with Gland’s operations to unlock synergies and efficiency gains. * **DRL Revenue Isolation:** DRL-related revenues are currently recognized only in India, with no international market contribution yet reflected, suggesting potential for future reclassification or expansion. --- # 4. Manufacturing & Capacity ## A. Key Figures * Cartridge Fill/Finish Capacity: **40 Mn → 140 Mn units** (GLP-1, insulin) · **Initial 40 Mn units largely filled** * **Biologic CDMO Capacity:** **8 KL → 23 KL** (biosimilar/fill-finish expansion) ## B. Fill-Finish Expansion * **Strategic Scale-Up:** Cartridge capacity tripled to support **GLP-1 and insulin programs**, with flexible infrastructure enabling **cross-platform fill/finish** (vials, cartridges, syringes). * **Near-Term Utilization:** Initial 4 crore-unit capacity already largely contracted, with **full ramp-up expected by FY’28** over a two-year period. ## C. Site Recovery & Output * **Fontenay Recovery Complete:** GMP certification renewed through 2026; **ANSM observations resolved** post-July inspection, restoring full compliance. * **Hérouville Ramp-Up Accelerating:** Activity normalized with strong output growth driven by **inactivated vaccine and sterile ophthalmic gel** production. * **Operational Normalcy Achieved:** No inventory overhangs; all sites operating at expected levels. ## D. Capex & Capacity Build * **Multi-Technology Expansion:** Investments underway in **dry powder filling, ophthalmics, blow-fill-seal**, and **pen assembly**, targeting regulated and global markets. * **Growth-Funded Strategy:** Capex focused on **Pashamylaram site upgrades**, including insulin production and packaging lines, to capture biologic and CDMO demand. * **Future Capacity Additions:** **10 crore-unit expansion** under construction, set for H2 next year to support new contracts. ## E. Lyophilization Capacity * **Freeze-Dryer Qualification Advancing:** Two new units at Braine-l'Alleud on track for **2025 completion**, significantly boosting **lyophilization throughput**. --- # 5. R&D & Pipeline Progress ## A. Key Figures * R&D Expense: ₹614 Mn (5.8% of sales) Q2 FY26 (+25% YoY) · ₹1,075 Mn (5.1% of sales) H1 FY26 (+9% YoY) * **R&D as % of Revenue:** **6%** this quarter, up from prior periods * **Pipeline Output:** **6 ANDA filings**, **5 approvals**, **7 new U.S. product launches** ## B. ANDA Filings & Approvals * **Elevated R&D Intensity:** Increased spending reflects strategic focus on **complex injectables and next-gen delivery systems**, driving robust regulatory activity and product launches. * **Near-Term Commercial Catalyst:** **Three semaglutide products** filed, with commercial supply expected next year in select markets pending approvals. * **Cost Normalization Expected:** Current R&D intensity at 6% of revenue seen as temporary; management guides for **~5% annual run rate** going forward. ## C. Tech Transfer Projects * **High-Value Tech Transfers:** **Dalbavancin** and **CMS projects** underway, including a nearly **₹150 Cr on-market product transfer from Xellia**. --- # 6. Pricing & Demand Risks ## A. Key Figures * **Milestone Revenue:** **₹44–45 Cr** (current quarter) · **₹75–80 Cr** (normal run rate) ## B. Milestone Revenue Timing * **Sharp Decline in Milestone Income:** Revenue fell well below normal run-rate levels due to **slower U.S. licensing activity** and timing delays in development/filing milestones. * **Non-Core Revenue Stream:** Milestone receipts stem from **new product licenses**, not core sales of enoxa or heparin. ## C. CMO Market Conditions * **CMO Downturn Expected:** Business activity to remain weak near-term amid paused tech transfers, signaling continued headwinds. ## D. Regulatory Tariff Risk * **Tariff Relief Secured:** U.S. decision to withhold generic drug tariffs removes a key risk and bolsters Gland’s strategy to expand its **global supply chain footprint**. ## E. Product Mix Volatility * **Unreliable Pandemic Benchmark:** FY’23 enoxa and heparin sales were inflated by **COVID-driven demand**, limiting comparability for future growth assessments. --- # 7. Guidance & Outlook ## A. Key Figures * **Consolidated Revenue Growth Guidance:** **Mid-teens** (%) for FY26 · **Mid-teens** (%) for next 2 years * **Cenexi Revenue Run Rate:** **€50 Mn** from Q3 FY26 * **Cenexi EBITDA Loss Reduction:** From **€11 Mn** to **€5 Mn** * **Capex Guidance:** **₹250 Cr** for Gland base business in FY26 · **₹300 Cr** next year ## B. Full-Year Revenue View * **Sustained Growth Trajectory:** Confidence in mid-teens consolidated growth underpinned by new product launches and expanded capabilities, with Cenexi providing a currency-boosted tailwind. * **Strategic Focus:** Gland’s pivot toward becoming an innovation-led, capital-efficient injectables and CDMO leader emphasizes high-quality earnings and **ROCE-driven execution**. ## C. Cenexi Breakeven Path * **Transformation on Track:** Cenexi’s EBITDA loss halved as strategic levers—**price increases, back-office consolidation in India, and capacity expansion**—gain traction. * **Breakeven Confirmed:** EBITDA positivity expected by end of Q3 or Q4 FY26, achievable even below €50 Mn revenue, signaling operational resilience. * **Growth Momentum:** **4 new project wins** this quarter validate shift to higher-value offerings and support sustainable revenue trajectory. ## D. H2 Growth Drivers * **Strong H2 Expected:** Growth acceleration anticipated on back of **Dalbavancin launch**, volume gains, CDMO wins, and Cenexi improvements. * **Timing & Pipeline Dynamics:** Initial Dalbavancin revenue surge expected this quarter due to **pipeline fill**, while cangrelor launch delayed by patent timelines. * **Client Work Ramp-Up:** Increased activity from **Lilly and DRL** underway, though revenue impact to lag by a few quarters. ## E. Margin Sustainability * **Efficiency Drive Intensifying:** Company-wide cost discipline, **API supplier diversification**, and **low-margin product pruning** aimed at structural margin enhancement. * **Capex Ramping:** Investment increasing to support future capacity and capabilities, with base business spend rising to ₹300 Cr next year.